Deposition of discrete nanoparticles on a nanostructured surface of an implant
US-9204944-B2 · Dec 8, 2015 · US
US2019201576A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2019201576-A1 |
| Application number | US-201716328677-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 21, 2017 |
| Priority date | Sep 8, 2016 |
| Publication date | Jul 4, 2019 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided is a biocompatible alloy having low magnetic susceptibility and excellent mechanical properties. The biocompatible alloy according to the present invention contains: Zr as a main component; Nb of not less than 0.1% by mass and not greater than 25% by mass; Mo of not less than 0.1% by mass and not greater than 25% by mass; and Ta of not less than 0.1% by mass and not greater than 25% by mass. A total content of Nb, Mo, and Ta in the biocompatible alloy is not less than 2% by mass and not greater than 50% by mass. The biocompatible alloy has a mass susceptibility of not greater than 1.50×10−6 cm3/g. The biocompatible alloy has a Young's Modulus of not greater than 100 GPa. Various biocompatible implants and medical devices can be manufactured from the biocompatible alloy.
Opening claim text (preview).
1 . A biocompatible alloy comprising: Zr as a main component; Nb of not less than 0.1% by mass and not greater than 25% by mass; Mo of not less than 0.1% by mass and not greater than 25% by mass; and Ta of not less than 0.1% by mass and not greater than 25% by mass. 2 . The biocompatible alloy according to claim 1 , wherein a total content of Nb, Mo, and Ta is not less than 2% by mass and not greater than 50% by mass. 3 . The biocompatible alloy according to claim 1 , wherein the Nb content is not less than 0.5% by mass and not greater than 25% by mass, the Mo content is not less than 0.1% by mass and not greater than by mass, and the Ta content is not less than 1.0% by mass and not greater than 15% by mass. 4 . The biocompatible alloy according to claim 1 , wherein the Nb content is not less than 12% by mass and not greater than 16% by mass, the Mo content is not less than 0.5% by mass and not greater than 5% by mass, and the Ta content is not less than 3% by mass and not greater than 12% by mass. 5 . The biocompatible alloy according to claim 1 , wherein a ratio (PMo/PTa) of PMo, which is the Mo content (% by mass), to PTa, which is the Ta content (% by mass), is not less than 1/20 and not greater than 1/3. 6 . The biocompatible alloy according to claim 1 , wherein the biocompatible alloy has a mass susceptibility of not greater than 1.50×10 −6 cm 3 /g. 7 . The biocompatible alloy according to claim 1 , wherein the biocompatible alloy has a Young's Modulus of not greater than 100 GPa. 8 . A medical product made of the biocompatible alloy according to claim 1 .
comprising metals or alloys · CPC title
Inorganic materials · CPC title
Metals or alloys · CPC title
Metals or alloys · CPC title
Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.